CL2016001441A1 - Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes. - Google Patents

Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes.

Info

Publication number
CL2016001441A1
CL2016001441A1 CL2016001441A CL2016001441A CL2016001441A1 CL 2016001441 A1 CL2016001441 A1 CL 2016001441A1 CL 2016001441 A CL2016001441 A CL 2016001441A CL 2016001441 A CL2016001441 A CL 2016001441A CL 2016001441 A1 CL2016001441 A1 CL 2016001441A1
Authority
CL
Chile
Prior art keywords
ror
disorders
useful
treatment
1hpyrrolo
Prior art date
Application number
CL2016001441A
Other languages
English (en)
Inventor
Sanjib Das
Sachin Sundarlal Chaudhari
Abraham Thomas
Shailesh Ramesh Pardeshi
Vishal Govindrao Deshmukh
Prashant Dilip Wadekar
Neelima Khairatkar-Joshi
Daisy Manish Shah
Malini Bajpai
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of CL2016001441A1 publication Critical patent/CL2016001441A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (i) y sales farmacéuticamente aceptables de los mismos, en la cual x, x1, m, r2, r3, r4, r5, m, n, y p son como se definen en la presente, los cuales son activos como moduladores del receptor gamma t huérfano (ror?t) relacionado con retinoides. estos compuestos previenen, inhibir, o suprimen la acción de ror?t y por lo tanto son útiles en el tratamiento de enfermedades, trastornos, síndromes o afecciones mediados por ror?t tales como, por ejemplo, d
CL2016001441A 2013-12-10 2016-06-10 Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes. CL2016001441A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3853MU2013 2013-12-10
IN527MU2014 2014-02-14
IN2172MU2014 2014-07-04

Publications (1)

Publication Number Publication Date
CL2016001441A1 true CL2016001441A1 (es) 2017-03-03

Family

ID=52355020

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001441A CL2016001441A1 (es) 2013-12-10 2016-06-10 Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes.

Country Status (18)

Country Link
US (1) US9682977B2 (es)
EP (1) EP3080090B1 (es)
JP (1) JP2016539989A (es)
CN (1) CN105980364A (es)
AP (1) AP2016009281A0 (es)
AU (1) AU2014363035A1 (es)
BR (1) BR112016013425A2 (es)
CA (1) CA2933003A1 (es)
CL (1) CL2016001441A1 (es)
EA (1) EA029489B1 (es)
IL (1) IL246123A0 (es)
MX (1) MX2016007604A (es)
PE (1) PE20160687A1 (es)
PH (1) PH12016501105A1 (es)
SG (1) SG11201604714SA (es)
TW (1) TW201605797A (es)
WO (1) WO2015087234A1 (es)
ZA (1) ZA201604454B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419015D0 (en) * 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
WO2017051319A1 (en) * 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
EP3368516B1 (en) * 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
RU2742770C1 (ru) * 2017-07-06 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное индола и формамида, способ его получения и применение в медицине
CN110945002B (zh) * 2017-08-01 2021-12-24 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621237A (en) * 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
EP1837329A4 (en) * 2005-01-14 2009-08-05 Dainippon Sumitomo Pharma Co NEW HETEROARYL DERIVATIVE
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator

Also Published As

Publication number Publication date
CA2933003A1 (en) 2015-06-18
CN105980364A (zh) 2016-09-28
JP2016539989A (ja) 2016-12-22
EP3080090A1 (en) 2016-10-19
BR112016013425A2 (pt) 2017-08-08
SG11201604714SA (en) 2016-07-28
EA201691002A1 (ru) 2016-12-30
EP3080090B1 (en) 2018-01-31
MX2016007604A (es) 2017-02-28
IL246123A0 (en) 2016-08-02
WO2015087234A1 (en) 2015-06-18
TW201605797A (zh) 2016-02-16
ZA201604454B (en) 2017-11-29
EA029489B1 (ru) 2018-04-30
US20160326163A1 (en) 2016-11-10
AP2016009281A0 (en) 2016-06-30
PH12016501105A1 (en) 2016-07-11
PE20160687A1 (es) 2016-08-11
AU2014363035A1 (en) 2016-06-30
US9682977B2 (en) 2017-06-20

Similar Documents

Publication Publication Date Title
MX2020000968A (es) Compuestos organicos.
MX2021013564A (es) Gamma-carbolinas fusionadas con heterociclo deuterado.
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2016013046A (es) Compuestos organicos.
MX2016012103A (es) Agonistas del receptor muscarinico.
MX2018009158A (es) Compuestos organicos.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2014012374A (es) Compuestos organicos.
MX2017015521A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
CU20150056A7 (es) Derivados e 1h- bencimidazol como antagonistas de ep4 y medicamentos que los contienen
CR20180185A (es) Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
CL2018000292A1 (es) Compuestos farmacéuticos
MX2017014621A (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma.
PE20160687A1 (es) Analogos de heteroaril indol biciclico utiles como moduladores de ror
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2018002326A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
MX2017014375A (es) Moduladores del ccr2.
CL2013001772A1 (es) Compuestos derivados de indol y azaindol, como inhibidores de la faah; composicion farmaceutica que los comprende, util para el tratamiento o prevencion del dolor, trastornos autoinmunes, procesos inflamatorios, enfermedades gastrointestinales, prurito, enfermedad relacionada con abuso de sustancias, entre otras enfermedades.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CL2018000289A1 (es) Compuestos nuevos como moduladores de ror gamma.
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos